CohBar’s CEO to Participate in Upcoming BIO Webinar

Nov 29, 2021

CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 15, 2021

CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021

Nov 1, 2021

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

Oct 28, 2021

CohBar Announces Proposed Public Offering of Common Stock and Warrants

Oct 27, 2021

CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021

Oct 13, 2021

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

Oct 5, 2021

CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

Sep 15, 2021

CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)

Sep 8, 2021

CohBar to Present at Upcoming Investor Conferences

Sep 2, 2021